On 1/2/25, Avalo Therapeutics Inc (NASDAQ: AVTX) stock enjoyed a major increase of 13.5%, closing at $8.43. NORMAL trading volume accompanied the advance. The stock has been weak relative to the market over the last nine months and has declined -7.3% during the last week.
Current PriceTarget Research Rating
Avalo Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Avalo Therapeutics has a slightly negative Appreciation Score of 34 and a poor Power Rating of 20, and the Lowest Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment